Global Arbidol Tablets (COVID-19) Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Arbidol Tablets (COVID-19) Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Arbidol Hydrochloride as known as Arbidol, is an antiviral treatment for influenza infection.
Arbidol Tablets (COVID-19) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Arbidol Tablets (COVID-19) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Anti Influenza Virus and COVID-19 are the major drivers for the industry.
In February 2020, Li Lanjuan, an expert of the National Health Commission of China, proposed using Arbidol (umifenovir) together with darunavir as a potential treatment during the 2019–20 coronavirus outbreak. Chinese experts claim that preliminary tests had shown that arbidol and darunavir could inhibit replication of the virus. However, later studies showed that it did not show any efficacy in treating the Covid-19 disease. However usage by itself as a post-exposure prophylaxis (PEP) of Covid-19 transmission has been demonstrating positive results though further research is still warranted.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Arbidol Tablets (COVID-19) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
JSC Pharmstandard
Jiangsu Wuzhong Pharmaceutical
CSPC Ouyi Pharmaceutical
Simcere Pharmaceutical
Segment by Type
50mg
100mg
Anti Influenza Virus
COVID-19
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Arbidol Tablets (COVID-19) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Arbidol Tablets (COVID-19), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Arbidol Tablets (COVID-19) industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Arbidol Tablets (COVID-19) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Arbidol Tablets (COVID-19) introduction, etc. Arbidol Tablets (COVID-19) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Arbidol Tablets (COVID-19) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Arbidol Tablets (COVID-19) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Arbidol Tablets (COVID-19) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Anti Influenza Virus and COVID-19 are the major drivers for the industry.
In February 2020, Li Lanjuan, an expert of the National Health Commission of China, proposed using Arbidol (umifenovir) together with darunavir as a potential treatment during the 2019–20 coronavirus outbreak. Chinese experts claim that preliminary tests had shown that arbidol and darunavir could inhibit replication of the virus. However, later studies showed that it did not show any efficacy in treating the Covid-19 disease. However usage by itself as a post-exposure prophylaxis (PEP) of Covid-19 transmission has been demonstrating positive results though further research is still warranted.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Arbidol Tablets (COVID-19) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
JSC Pharmstandard
Jiangsu Wuzhong Pharmaceutical
CSPC Ouyi Pharmaceutical
Simcere Pharmaceutical
Segment by Type
50mg
100mg
Segment by Application
Anti Influenza Virus
COVID-19
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Arbidol Tablets (COVID-19) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Arbidol Tablets (COVID-19), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Arbidol Tablets (COVID-19) industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Arbidol Tablets (COVID-19) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Arbidol Tablets (COVID-19) introduction, etc. Arbidol Tablets (COVID-19) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Arbidol Tablets (COVID-19) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices